AP-1531 is a potent and selective EP4 receptor antagonist that targets PGE2-EP4 binding which may treat migraines.
In earlier studies, AP-1531 has demonstrated positive results in several disease models of migraine and acute pain and inflammation.
Ariel Pharma president and CEO Steve Orndorff said they believe AP-1531 will validate their business model of in-licensing clinic-ready drugs in acute care clinical indications to expeditiously build value for their shareholders.